While a head-to-head comparison of NHAIDHwt and NHAIDHmut tumors is not possible in vivo due to the lack of tumorigenicity of the NHAIDHwt cells, a comparison of patient-derived mutant IDH1 models, such as BT142, with wild-type IDH1 glioblastoma models, such as the U87 model, is feasible and provides a clinically relevant comparison. The gene discussed is IDH1; the disease is glioblastoma.